• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

Introduction to 1-(3-Methylphenyl)cyclobutanecarboxylic Acid (CAS No. 202737-32-4)

1-(3-Methylphenyl)cyclobutanecarboxylic Acid, identified by its Chemical Abstracts Service (CAS) number 202737-32-4, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of cyclobutane derivatives coupled with an aromatic ring, featuring a unique structural configuration that makes it a promising candidate for various biochemical applications. The presence of a 3-methylphenyl group (also known as *p*-tolyl) introduces a specific electronic and steric environment, which can influence its interactions with biological targets, making it an intriguing subject for further investigation.

The molecular structure of 1-(3-Methylphenyl)cyclobutanecarboxylic Acid consists of a cyclobutane ring substituted with a carboxylic acid moiety at one position and a 3-methylphenyl group at another. This arrangement imparts distinct physicochemical properties, such as solubility, stability, and reactivity, which are critical factors in drug design and development. The compound’s ability to engage in hydrogen bonding due to the carboxylic acid group, combined with its aromatic nature, suggests potential applications in the synthesis of enzyme inhibitors, receptor modulators, and other therapeutic agents.

In recent years, there has been growing interest in cyclobutane derivatives due to their unique biological activities and synthetic versatility. The rigid cyclic structure of the cyclobutane ring can enhance binding affinity and selectivity towards certain biological targets, which is a key consideration in medicinal chemistry. Specifically, 1-(3-Methylphenyl)cyclobutanecarboxylic Acid has been explored in the context of developing novel pharmacological entities that could address unmet medical needs. Its structural motif is reminiscent of established drug scaffolds, suggesting that it may serve as a valuable building block for further derivatization and optimization.

One of the most compelling aspects of 1-(3-Methylphenyl)cyclobutanecarboxylic Acid is its potential role in modulating biological pathways associated with inflammation, pain perception, and neurodegenerative disorders. Preclinical studies have indicated that structurally similar compounds can interact with specific enzymes and receptors, leading to therapeutic effects. For instance, derivatives of cyclobutane carboxylic acids have been investigated for their anti-inflammatory properties by targeting cyclooxygenase (COX) enzymes or other inflammatory mediators. The 3-methylphenyl substituent may further enhance these interactions by influencing the compound’s electronic properties and binding affinity.

The synthesis of 1-(3-Methylphenyl)cyclobutanecarboxylic Acid presents both challenges and opportunities for chemists. Traditional synthetic routes often involve multi-step processes that require careful control of reaction conditions to achieve high yields and purity. Advances in catalytic methods and asymmetric synthesis have made it possible to construct complex molecules more efficiently. Additionally, computational chemistry techniques are increasingly being employed to predict the behavior of such compounds before experimental synthesis, thereby reducing trial-and-error approaches. These innovations are crucial for optimizing the production of 1-(3-Methylphenyl)cyclobutanecarboxylic Acid and its derivatives.

From a pharmaceutical perspective, the development of new drug candidates relies heavily on understanding the relationship between molecular structure and biological activity. 1-(3-Methylphenyl)cyclobutanecarboxylic Acid exemplifies this principle by combining structural features that are known to enhance pharmacological potency. Its cyclobutane core provides rigidity, while the carboxylic acid group allows for further functionalization through esterification or amidation reactions. The 3-methylphenyl moiety contributes to lipophilicity and can be modified to improve solubility or target specificity.

Recent research has also explored the use of 1-(3-Methylphenyl)cyclobutanecarboxylic Acid as an intermediate in the synthesis of more complex molecules with tailored biological activities. For example, researchers have investigated its potential as a precursor for designing small-molecule inhibitors targeting protein-protein interactions or enzyme-substrate complexes. The versatility of this compound lies in its ability to serve as a scaffold for structural diversification while maintaining key pharmacophoric elements necessary for biological activity.

In conclusion, 1-(3-Methylphenyl)cyclobutanecarboxylic Acid (CAS No. 202737-32-4) represents a fascinating compound with significant potential in pharmaceutical research and drug development. Its unique structural features make it an attractive candidate for further exploration in medicinal chemistry. As our understanding of biochemical pathways continues to expand, compounds like this one will play an increasingly important role in addressing complex diseases through innovative therapeutic strategies.

• 1483293-27-1(2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid)
• 202737-37-9(2-phenylspiro[3.3]heptane-2-carboxylic acid)
• 50921-38-5(1-(4-methylphenyl)cyclobutane-1-carboxylic acid)
• 926187-55-5(1-[4-(propan-2-yl)phenyl]cyclobutane-1-carboxylic acid)
• 633317-67-6(2-methyl-1-phenylcyclobutane-1-carboxylic acid)
• 926223-33-8(1-(3,5-Dimethylphenyl)cyclobutane-1-carboxylic acid)
• 37828-19-6(1-phenylcyclobutane-1-carboxylic acid)
• 26961-85-3(Cyclobutanecarboxylicacid, 1-(4-cyclohexylphenyl)-)
• 926247-18-9(1-(4-tert-butylphenyl)cyclobutane-1-carboxylic acid)
• 151157-51-6(3,3-dimethyl-1-phenyl-cyclobutanecarboxylic acid)